ScholarLens Back to search
2004•PubMedRequires access

Tegaserod in patients with irritable bowel syndrome.

Michael Schooff, Casey Stelter

Open publisher page 0 citations

Abstract

Tegaserod offers modest improvement in global gastrointestinal (GI) symptoms in women with constipation-predominant IBS, without having significant effect on symptoms of abdominal pain and discomfort.

About this research paper

What this paper is about

Tegaserod offers modest improvement in global gastrointestinal (GI) symptoms in women with constipation-predominant IBS, without having significant effect on symptoms of abdominal pain and discomfort.

Why it matters

A significance statement is not available in the OpenAlex record.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Tegaserod offers modest improvement in global gastrointestinal (GI) symptoms in women with constipation-predominant IBS, without having significant effect on symptoms of abdominal pain and discomfort.

Key concepts: Tegaserod, Medicine, Irritable bowel syndrome, Gastroenterology, Internal medicine

Related papers

Related paper 1Related paper 2Related paper 3
Back to paper searchBrowse research topicsOriginal source
Tegaserod in patients with irritable bowel syndrome. — Research Paper | ScholarLens